Overview

Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This is a confirmatory, randomized, placebo-controlled, multi-center, double-blinded phase II/III study. The study population consists of male or female intensive care unit (ICU) patients with a need for mechanical ventilation for more than 48 hours, aged between 18 and 80 years.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Valneva Austria GmbH